Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure

Gianluigi Ardissino, Claus Peter Schmitt, Sara Testa, Aldo Claris-Appiani, Otto Mehls

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Calcitriol oral pulse therapy has been suggested as the treatment of choice for secondary hyperparathyroidism, but its efficacy and safety are still under discussion. The present randomized multicenter study compares the effect of an 8-week course of daily versus intermittent (twice weekly) calcitriol therapy on parathyroid hormone (PTH) suppression in 59 children (mean age 8.4 ± 4.7 years) with chronic renal insufficiency (mean C(cr) 22.4 ± 11.6 ml/min per 1.73 m2) and secondary hyperparathyroidism. After a 3-week washout period, the patients were randomly assigned to treatment with daily oral calcitriol (10 ng/kg per day) or intermittent oral calcitriol (35 ng/kg given twice a week). The calcitriol dose was not changed throughout the study period of 8 weeks. At start of the study, the median intact PTH (iPTH) level was 485 pg/ml (range 83-2032) in the daily group (n = 29) and 315 pg/ml (range 93-1638) in the intermittent group (n = 30). After 8 weeks, the respective median iPTH concentrations were 232 pg/ml (range 63-1614) and 218 pg/ml (range 2-1785) (ns). The mean iPTH decrease from baseline was 19.2 ± 57.8% and 13.7 ± 46.7% respectively (not significant). Calcitriol reduced the iPTH concentration in 23/29 patients in the daily group and in 21/30 in the intermittent group. One episode of hypercalcemia (> 11.5 mg/dl) was observed in both groups and a single episode of hyperphosphatemia (> 7.5 mg/dl) was observed in the daily group. It is concluded that oral calcitriol pulse therapy does not control secondary hyperparathyroidism more effectively than the daily administration of calcitriol in children with chronic renal failure prior to dialysis.

Original languageEnglish
Pages (from-to)664-668
Number of pages5
JournalPediatric Nephrology
Volume14
Issue number7
Publication statusPublished - Jul 2000

Fingerprint

Secondary Hyperparathyroidism
Calcitriol
Chronic Kidney Failure
Therapeutics
Parathyroid Hormone
Hyperphosphatemia
Hypercalcemia
Chronic Renal Insufficiency
Multicenter Studies
Dialysis
Safety

Keywords

  • Chronic renal failure
  • Intermittent calcitriol
  • Pulse calcitriol
  • Secondary hyperparathyroidism

ASJC Scopus subject areas

  • Nephrology
  • Pediatrics, Perinatology, and Child Health

Cite this

Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure. / Ardissino, Gianluigi; Schmitt, Claus Peter; Testa, Sara; Claris-Appiani, Aldo; Mehls, Otto.

In: Pediatric Nephrology, Vol. 14, No. 7, 07.2000, p. 664-668.

Research output: Contribution to journalArticle

@article{adba8ca0253c4065aa444910c2595549,
title = "Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure",
abstract = "Calcitriol oral pulse therapy has been suggested as the treatment of choice for secondary hyperparathyroidism, but its efficacy and safety are still under discussion. The present randomized multicenter study compares the effect of an 8-week course of daily versus intermittent (twice weekly) calcitriol therapy on parathyroid hormone (PTH) suppression in 59 children (mean age 8.4 ± 4.7 years) with chronic renal insufficiency (mean C(cr) 22.4 ± 11.6 ml/min per 1.73 m2) and secondary hyperparathyroidism. After a 3-week washout period, the patients were randomly assigned to treatment with daily oral calcitriol (10 ng/kg per day) or intermittent oral calcitriol (35 ng/kg given twice a week). The calcitriol dose was not changed throughout the study period of 8 weeks. At start of the study, the median intact PTH (iPTH) level was 485 pg/ml (range 83-2032) in the daily group (n = 29) and 315 pg/ml (range 93-1638) in the intermittent group (n = 30). After 8 weeks, the respective median iPTH concentrations were 232 pg/ml (range 63-1614) and 218 pg/ml (range 2-1785) (ns). The mean iPTH decrease from baseline was 19.2 ± 57.8{\%} and 13.7 ± 46.7{\%} respectively (not significant). Calcitriol reduced the iPTH concentration in 23/29 patients in the daily group and in 21/30 in the intermittent group. One episode of hypercalcemia (> 11.5 mg/dl) was observed in both groups and a single episode of hyperphosphatemia (> 7.5 mg/dl) was observed in the daily group. It is concluded that oral calcitriol pulse therapy does not control secondary hyperparathyroidism more effectively than the daily administration of calcitriol in children with chronic renal failure prior to dialysis.",
keywords = "Chronic renal failure, Intermittent calcitriol, Pulse calcitriol, Secondary hyperparathyroidism",
author = "Gianluigi Ardissino and Schmitt, {Claus Peter} and Sara Testa and Aldo Claris-Appiani and Otto Mehls",
year = "2000",
month = "7",
language = "English",
volume = "14",
pages = "664--668",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure

AU - Ardissino, Gianluigi

AU - Schmitt, Claus Peter

AU - Testa, Sara

AU - Claris-Appiani, Aldo

AU - Mehls, Otto

PY - 2000/7

Y1 - 2000/7

N2 - Calcitriol oral pulse therapy has been suggested as the treatment of choice for secondary hyperparathyroidism, but its efficacy and safety are still under discussion. The present randomized multicenter study compares the effect of an 8-week course of daily versus intermittent (twice weekly) calcitriol therapy on parathyroid hormone (PTH) suppression in 59 children (mean age 8.4 ± 4.7 years) with chronic renal insufficiency (mean C(cr) 22.4 ± 11.6 ml/min per 1.73 m2) and secondary hyperparathyroidism. After a 3-week washout period, the patients were randomly assigned to treatment with daily oral calcitriol (10 ng/kg per day) or intermittent oral calcitriol (35 ng/kg given twice a week). The calcitriol dose was not changed throughout the study period of 8 weeks. At start of the study, the median intact PTH (iPTH) level was 485 pg/ml (range 83-2032) in the daily group (n = 29) and 315 pg/ml (range 93-1638) in the intermittent group (n = 30). After 8 weeks, the respective median iPTH concentrations were 232 pg/ml (range 63-1614) and 218 pg/ml (range 2-1785) (ns). The mean iPTH decrease from baseline was 19.2 ± 57.8% and 13.7 ± 46.7% respectively (not significant). Calcitriol reduced the iPTH concentration in 23/29 patients in the daily group and in 21/30 in the intermittent group. One episode of hypercalcemia (> 11.5 mg/dl) was observed in both groups and a single episode of hyperphosphatemia (> 7.5 mg/dl) was observed in the daily group. It is concluded that oral calcitriol pulse therapy does not control secondary hyperparathyroidism more effectively than the daily administration of calcitriol in children with chronic renal failure prior to dialysis.

AB - Calcitriol oral pulse therapy has been suggested as the treatment of choice for secondary hyperparathyroidism, but its efficacy and safety are still under discussion. The present randomized multicenter study compares the effect of an 8-week course of daily versus intermittent (twice weekly) calcitriol therapy on parathyroid hormone (PTH) suppression in 59 children (mean age 8.4 ± 4.7 years) with chronic renal insufficiency (mean C(cr) 22.4 ± 11.6 ml/min per 1.73 m2) and secondary hyperparathyroidism. After a 3-week washout period, the patients were randomly assigned to treatment with daily oral calcitriol (10 ng/kg per day) or intermittent oral calcitriol (35 ng/kg given twice a week). The calcitriol dose was not changed throughout the study period of 8 weeks. At start of the study, the median intact PTH (iPTH) level was 485 pg/ml (range 83-2032) in the daily group (n = 29) and 315 pg/ml (range 93-1638) in the intermittent group (n = 30). After 8 weeks, the respective median iPTH concentrations were 232 pg/ml (range 63-1614) and 218 pg/ml (range 2-1785) (ns). The mean iPTH decrease from baseline was 19.2 ± 57.8% and 13.7 ± 46.7% respectively (not significant). Calcitriol reduced the iPTH concentration in 23/29 patients in the daily group and in 21/30 in the intermittent group. One episode of hypercalcemia (> 11.5 mg/dl) was observed in both groups and a single episode of hyperphosphatemia (> 7.5 mg/dl) was observed in the daily group. It is concluded that oral calcitriol pulse therapy does not control secondary hyperparathyroidism more effectively than the daily administration of calcitriol in children with chronic renal failure prior to dialysis.

KW - Chronic renal failure

KW - Intermittent calcitriol

KW - Pulse calcitriol

KW - Secondary hyperparathyroidism

UR - http://www.scopus.com/inward/record.url?scp=0034045940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034045940&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 664

EP - 668

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 7

ER -